VSTM

VerastemD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

25%

Probability

Target price

$10.50

+175.6% vs current

Most likely

Base case

45%

Probability

Target price

$6.75

+77.2% vs current

B-

Bear case

30%

Probability

Target price

$3.25

-14.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Tone is mixed-to-negative on a T+1 basis. The company delivered a legitimate commercial revenue print and reiterated multiple 2026 data milestones through its May 7 materials, but live market pricing on May 8 showed a roughly 14% drop from the May 7 close of $5.66 to about $4.87, implying the market focused more on financing runway, burn, and the going-concern disclosure than on the topline launch progression. Analyst revision evidence was not clearly available yet, which supports cautious monitoring language rather than a stronger post-earnings upgrade.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-08catalystPost-earnings digestion is centered on launch traction versus funding riskHigh impact

Q1 2026 product revenue was $18.671 million, net loss narrowed to $36.6 million, and cash, cash equivalents and restricted cash ended the quarter at $165.8 million, but the 10-Q also states substantial doubt about the company’s ability to continue as a going concern within twelve months absent additional capital or sufficient commercialization progress [#10-Q-2026-05-07].

2026-08-06eventRAMP 205 pancreatic update is a near-term clinical checkpointHigh impact

The May 2026 corporate presentation furnished with the May 7, 2026 8-K says Verastem expects a Q2 2026 update on the safety and efficacy of the RAMP 205 expansion cohort with six months of follow-up on all patients, making this one of the clearest upcoming data events [#8-K-2026-05-07].

2027-05-08catalystVS-7375 early data and registration-directed path remain the main upside leverHigh impact

The May 2026 corporate presentation says Verastem expects an early 1H 2026 data update from TARGET-D 101 for VS-7375 and is targeting first-patient-in around mid-2026 for TARGET-D 201, 202 and 203, which could define whether the KRAS G12D program supports a broader rerating beyond the current AVMAPKI launch story [#8-K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology